加载中
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
前收盘价
US$4.65
+US$0.19 · +4.26%
盘中时间采用ET。市场数据可能有所延迟。
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
日内区间
当前US$4.65
52周区间
当前US$4.65
盘中时间采用ET。市场数据可能有所延迟。
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
日内区间
当前US$4.65
52周区间
当前US$4.65
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1419.6万 USD | 1099.2万 USD | 1904.9万 USD | 3985万 USD | 58.9万 USD |
| 毛利 | 1419.6万 USD | 1099.2万 USD | 1904.9万 USD | 3985万 USD | 58.9万 USD |
| 研究与开发 | 3081.2万 USD | 2685.1万 USD | 1765.3万 USD | 1435.5万 USD | 1517.3万 USD |
| 销售、一般及管理费用 | 2198.3万 USD | 1821.5万 USD | 1195.9万 USD | 726.9万 USD | 812.1万 USD |
| 营业费用 | 5279.5万 USD | 7306.6万 USD | 2961.2万 USD | 2162.4万 USD | 2329.4万 USD |
| 利息支出 | 146.6万 USD | — | 132.8万 USD | 9000 USD | 2000 USD |
| 折旧和摊销 | 5.3万 USD | 1万 USD | 6000 USD | 4000 USD | 4000 USD |
| 营业利润 | −3859.9万 USD | −6207.4万 USD | −1056.3万 USD | 1822.6万 USD | −2270.5万 USD |
| 净利润 | −4959.1万 USD | −5753.2万 USD | −998.6万 USD | 1788.8万 USD | −5669.3万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2020年11月6日 | 1:4 | — | — |
股票拆分 | 2019年4月12日 | 1:12 | — | — |
股票拆分 | 2017年5月5日 | 1:10 | — | — |
股票拆分 | 2005年5月23日 | 1:100 | — | — |
已生效 2020年11月6日
1:4
已生效 2019年4月12日
1:12
已生效 2017年5月5日
1:10
已生效 2005年5月23日
1:100
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM812.33万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI810.66万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 Growth ETFIWO283.55万0.02%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF236.12万0.00%954亿 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO111.68万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC98.39万0.07%13.17亿 USD0.60%US$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC41.34万0.04%10.45亿 USD0.20%US$86.29+0.43%
Fidelity Enhanced Small Cap ETFFESM38.16万0.01%64.1亿 USD0.28%US$45.46+0.46%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
